BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4 AND Clinical Outcome
16 results:

  • 1. Patterns of biomarker expression in patients treated with primary endocrine therapy - a unique insight using core needle biopsy tissue microarray.
    Parks RM; Albanghali MA; Syed BM; Green AR; Ellis IO; Cheung KL
    Breast Cancer Res Treat; 2021 Feb; 185(3):647-655. PubMed ID: 33226492
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and breast cancer Cell Motility via Hypoxia-Inducible Factor 1α.
    Lopez-Haber C; Barrio-Real L; Casado-Medrano V; Kazanietz MG
    Mol Cell Biol; 2016 Aug; 36(15):2011-26. PubMed ID: 27185877
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing breast cancer.
    Menyhárt O; Santarpia L; Győrffy B
    Curr Cancer Drug Targets; 2015; 15(8):665-83. PubMed ID: 26452383
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Roles of the WWOX in pathogenesis and endocrine therapy of breast cancer.
    Li J; Liu J; Ren Y; Liu P
    Exp Biol Med (Maywood); 2015 Mar; 240(3):324-8. PubMed ID: 25476151
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. her4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.
    Portier BP; Minca EC; Wang Z; Lanigan C; Gruver AM; Downs-Kelly E; Budd GT; Tubbs RR
    Oncotarget; 2013 Oct; 4(10):1662-72. PubMed ID: 24091566
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts.
    Syed BM; Green AR; Paish EC; Soria D; Garibaldi J; Morgan L; Morgan DA; Ellis IO; Cheung KL
    Br J Cancer; 2013 Mar; 108(5):1042-51. PubMed ID: 23462719
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A five-gene model predicts clinical outcome in ER+/PR+, early-stage breast cancers treated with adjuvant tamoxifen.
    Kerr DA; Wittliff JL
    Horm Cancer; 2011 Oct; 2(5):261-71. PubMed ID: 21826535
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.
    Powe DG; Voss MJ; Habashy HO; Zänker KS; Green AR; Ellis IO; Entschladen F
    Breast Cancer Res Treat; 2011 Nov; 130(2):457-63. PubMed ID: 21298476
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.
    Jin Q; Esteva FJ
    J Mammary Gland Biol Neoplasia; 2008 Dec; 13(4):485-98. PubMed ID: 19034632
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and her4 in 278 breast cancer patients.
    Sassen A; Rochon J; Wild P; Hartmann A; Hofstaedter F; Schwarz S; Brockhoff G
    Breast Cancer Res; 2008; 10(1):R2. PubMed ID: 18182100
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast.
    Lee Y; Cho S; Seo JH; Shin BK; Kim HK; Kim I; Kim A
    Am J Clin Pathol; 2007 Dec; 128(6):1041-9. PubMed ID: 18024331
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
    Giuliani R; Durbecq V; Di Leo A; Paesmans M; Larsimont D; Leroy JY; Borms M; Vindevoghel A; Jerusalem G; D'Hondt V; Dirix L; Canon JL; Richard V; Cocquyt V; Majois F; Reginster M; Demol J; Kains JP; Delree P; Keppens C; Sotiriou C; Piccart MJ; Cardoso F
    Eur J Cancer; 2007 Mar; 43(4):725-35. PubMed ID: 17251007
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients.
    Cicenas J; Urban P; Küng W; Vuaroqueaux V; Labuhn M; Wight E; Eppenberger U; Eppenberger-Castori S
    Eur J Cancer; 2006 Mar; 42(5):636-45. PubMed ID: 16414259
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Cleavable erbb4 isoform in estrogen receptor-regulated growth of breast cancer cells.
    Junttila TT; Sundvall M; Lundin M; Lundin J; Tanner M; Härkönen P; Joensuu H; Isola J; Elenius K
    Cancer Res; 2005 Feb; 65(4):1384-93. PubMed ID: 15735025
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling.
    Tovey SM; Witton CJ; Bartlett JM; Stanton PD; Reeves JR; Cooke TG
    Breast Cancer Res; 2004; 6(3):R246-51. PubMed ID: 15084248
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer.
    Ariazi EA; Clark GM; Mertz JE
    Cancer Res; 2002 Nov; 62(22):6510-8. PubMed ID: 12438245
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.